Glioblastoma (GBM) is the most common primary adult intracranial malignancy and carries a
dismal prognosis despite an aggressive multimodal treatment regimen that consists of …

OBJECTIVE Following resection of glioblastoma (GBM), microscopic remnants of the GBM
tumor remaining in nearby tissue cause tumor recurrence more often than for other types of …

We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a
retrospective series of uniformly treated glioblastoma patients. Patients were classified as …

Objective: To date, there are several published studies on the value of IDH-1 (isocitrate
dehydrogenase-1) mutation and MGMT (O6-Methylguanine-DNA methyltransferas) …

Background: Pseudoprogression (PsP) mimics true early progression (TeP) in conventional
imaging, which poses a diagnostic challenge in glioblastoma (GBM) patients who undergo …

Glioblastoma (GBM) is an aggressive central nervous system tumor with a poor prognosis.
This study was conducted to determine any comorbid medical conditions that are associated …

Purpose Glioblastoma multiforme (GBM) is the most common malignant brain tumor.
Moreover, GBM recurs in nearly all patients. Although a standard STUPP protocol has been …

Background The standard of care for glioblastoma multiforme (GBM) is maximal surgical
resection followed by conventional fractionated concurrent chemoradiotherapy (CCRT) with …

Introduction Currently, no single diagnostic modality allows the distinction between early
progression (EP) and pseudo-progression (Psp) in glioblastoma patients. Herein we aimed …

Background Pseudoprogression (psPD) represents false radiologic evidence of tumor
progression and is observed in some glioblastoma (GBM) patients after postoperative …